Artificial Intelligence in Thoracic Radiation Oncology: Treatment, Challenges, and Future Directions
+more
In part 2 of our look at AI’s impact on radiotherapy, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, discuss how AI may be leveraged when delivering radiotherapy, including improving our ability to predict treatment response and adverse events. Read more
Artificial Intelligence in Thoracic Radiation Oncology: Patient Evaluation and Treatment Planning
+more
In part 1 of a 2-part article, Grace Lee, MD, Fridolin Haugg, MSc, and Raymond H. Mak, MD, explore the possibilities and limitations of AI applications. Read more
In an interview with ILCN, Drs. Puneeth Iyengar and Matthias Guckenberger said despite a lack of phase III data in this space, science-based recommendations are needed to optimize multimodal therapy. Read more
Drs. Famke L. Schneiders and Suresh Senan explore evidence that supports the use of radiotherapy to prime the immune system to maximize the benefits of immunotherapy. Read more
Dr. Cole M. Friedes and colleagues analyzed progression patterns in patients after receiving the PACIFIC regimen and showed that many patients are candidates for further ablative treatments. Read more
During the 2023 World Conference on Lung Cancer, Dr. Stephen Chun said long-term data show intensity-modulated radiation therapy offers an overall survival benefit and reduced toxicity compared to 3D conformal radiation therapy. Read more
Dr. Jeffrey A. Bogart says that despite evidence that twice-daily radiotherapy has positive impacts on survival, the treatment has not been routinely adopted. However, considerable uncertainty remains regarding the optimal dose of once-daily radiotherapy. Read more
Researchers examine emerging data demonstrating that functionally distinct arrhythmia classes are associated with radiotherapy dose to discrete cardiac substructures. These observations may help guide potential mitigation efforts for lung cancer patients undergoing radiotherapy. Read more
Presenter Dr. Alex Brunelli says neoadjuvant chemoimmunotherapy is a promising and well-tolerated treatment option in select patients with stage III NSCLC. Read more
SABR patients were stable during the 12 months while surgical patients reported clinically significant deterioration at 6 weeks. Read more